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Abstract
Background: The family of zinc finger-containing GATA transcription factors plays critical roles in cell lineage specification
during early embryonic development and organ formation. GATA4 and GATA6 were found to be frequently lost in ovarian
cancer, and the loss is proposed to account for dedifferentiation of the cancer cells.
Methodology/Principal Findings: We further investigated the expression of GATA4 and GATA6 in ovarian surface epithelial
lesions and histological subtypes of ovarian carcinomas by immunostaining. GATA4 and GATA6 were found to be absent in
high percentages (80 to 90%) of serous, clear cell, and endometrioid ovarian cancer examined. In contrast, both were found
positive in 11 out of 12 cases of mucinous carcinomas, suggesting the expression of the GATA factors can distinguish
mucinous cancer from other histological subtypes. GATA4 was frequently lost in preneoplastic lesions such as
morphologically normal inclusion cysts and epithelial hyperplasia adjacent to malignant cells. The loss of GATA6 correlates
closely with neoplastic morphological transformation of ovarian surface epithelia. In culture, GATA4 expression was
progressively reduced upon passaging primary ovarian surface epithelial cells, which correlated with changes in histone
modification of the GATA4 locus. A reduced GATA6 gene dosage as in GATA6 (+/2) mice led to an increased pre-neoplastic
changes and inclusion cysts in the ovaries, suggesting the loss of GATA6 contributes to ovarian cancer development.
Conclusions/Significance: This study suggests that the expression status of GATA4 and GATA6 may dictate distinct
pathologic pathways leading to serous or mucinous ovarian carcinomas. The readily loss of GATA4 expression through
changes in chromatin conformation suggests a potential non-phenotypic initiating event, leading to subsequent loss of
GATA6, morphological transformation, and ultimate tumorigenesis.
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Introduction
Ovarian epithelial cancer is generally thought to arise from the
coelomic epithelium covering the ovarian surface [1,2] or from
inclusion cysts that are also thought to derive from the ovarian
surface epithelium [3,4]. However, there are also strong arguments
that at the least some of the ovarian epithelial cancer originated
from cells other than of the surface epithelia [5,6,7]. Several distinct
histological subtypes can be classified based on cell morphology:
these are serous, mucinous, clear cell, and endometroid subtypes
[8,9]. One idea to explain the diverse histological subtypes is that
ovarian surface epithelial cells undergo metaplasia to adopt various
histological characteristics during transformation [2,8]. Another
idea is that ovarian cancer may arise from the remains of mullerian
duct structures [6], which are precursors of the fallopian tubes,
cervix,uterus, etc, and maypresent asall the histological subtypes in
tumors. Indeed, recent observations lead to the hypothesis that a
significant portion of serous ovarian carcinomas may originate from
fallopian tubes [5,7], which have serous like epithelial cells.
Although some characteristics of the precursor cells may retain, the
distinction of cancer cellsfrom precursor cellsisapparent, and several
hallmarks of neoplastic cells have been recognized [10]. Unique
genetic mutations arethe basis for the neoplastic phenotypes [11–13],
and additionally cancer cells often appear in an inappropriately
differentiated stage, and the term ‘‘dedifferentiation’’ is often used
[14–16]. The phenotype described as ‘‘undifferentiated’’ or ‘‘dedif-
ferentiated’’ of ovarian cancer often refers to the apparent changes of
the cancer cells towards a less epithelial-like morphology or drift from
the precursor cells. To provide a molecular interpretation of
‘‘dedifferentiation’’ of cancer cells, one may consider the concept of
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which a primordial cell undergoes changes in its global gene
expression profile toward a specific mature cell type. By analogy,
dedifferentiation of cancer cells may be caused by the loss of one or
more critical genes that are key in inducing the differentiation of a
primordialcelltypetoyieldtheovariansurfaceepithelialcells.Recent
studies suggest the loss of the transcription factor GATA6 and
GATA4 in ovarian cancer may account for the loss of epithelial
characteristics and may be the underlying mechanism of ‘‘dediffer-
entiation’’ of ovarian cancer cells [17,18].
The GATA transcription factors bind a consensus A/T-G-A-T-
A-A/G sequence in promoters and are conserved in insects and
vertebrates, from fly to humans [19]. GATA4 and GATA6 are
expressed in most organs, and play critical roles in the development
of these organs [20,21]. GATA4 and GATA6 are first expressed
during the formation of extraembryonic endoderm differentiated
from the pluripotent embryonic stem cells of the inner cell mass
during early embryonic development [22–25]. GATA factors are
not tissue-specific but rather function in the specification and
differentiation of cell lineages within an organ, such as the
differentiation of an epithelial cell lineage from stromal cells.
GATA4 and GATA6 are expressed in human ovarian surface
epithelial cells [17,18], and presumably, GATA4 and GATA6 are
important for the formation and maintenance of the differentiated
state of ovarian surface epithelial cells. GATA4 and GATA6 are
often lost in ovarian cancer cells[17,26], and it is speculated that the
lossofthese developmentally important transcription factorsmaybe
the underlying mechanism of dedifferentiation [17,18].
Whether GATA6 is important for the formation of the ovarian
surface epithelium is unknown, since little is known about the
derivation of the ovarian surface epithelial cells. Both GATA4 and
GATA6 proteins are expressed in ovarian surface epithelial cells
but absent in most ovarian cancer cells [17,18,26]. We found by
ChIP assay that the histone H3 and H4 acetylation of the GATA4
locus decreased greatly in cancer cells comparing to GATA4-
positive non-tumor cells [18]. In contrast, histone H3 and H4
acetylation of the GATA6 locus in many cancer cells was not
reduced and traces of GATA6 mRNA could be detected by RT-
PCR, indicating that GATA6 gene is not transcriptionally silenced
but the message is suppressed by other mechanism(s) [18].
Few transcription targets for the GATA factors have been
identified, and Disabled-2 (Dab2) is a known transcription target of
GATA6 [27]. Dab2 was also found lost in ovarian cancer [28],
correlating with the absence of GATA6 and morphological
transformation [18]. Dab2 deficiency in mice leads to early
embryonic lethality [29–31], and heterozygous Dab2 mutant mice
develop pre-neoplastic lesions from ovarian surface epithelia [32].
Dab2 is an adaptor protein involved in endocytic trafficking, and
Dab2 plays a role in establishing epithelial polarity and surface
positioning [33]. Loss of Dab2 is thought to cause morphological
transformation of ovarian surface epithelia [34,35]. Thus, a
s p e c u l a t i o ni st h a tl o s so fG A T A 6w i l ll e a dt ol o s so fD a b 2a n d
neoplastic morphological transformation of ovarian surface epithelia.
In the current study, we further analyzed the details of GATA4
and GATA6 expression in ovarian tissues and cancer, and
examined the impact of the reduction of GATA6 in mice on
ovarian surface epithelial transformation.
Results
Expression of GATA4 and GATA6 in ovarian cancer
histological subtypes
Previously, both GATA4 and GATA6 were observed to be
strongly expressed in primary ovarian surface epithelial cells but
absent in cultured ovarian cancer cells by both Western blot to
examine the protein or Northern blot to measure mRNA [17,18].
With further development of antibodies and refinement of
staining procedure, we carried out immunohistochemical analysis
for the expression of GATA4 and GATA6 in a panel of ovarian
non-neoplastic and cancer tissues in tissue microarray (Table 1).
Additional 26 non-cancer ovarian tissues from prophylactic
oophorectomies were also used in this study. These ovarian tissues
were obtained from both high and normal risk women, but no
microscopic cancer was found [36]. The 111 informative ovarian
carcinomas in tissue microarray used in this study consist of 82
serous, 12 mucinous, 12 clear cell, and 5 endometrioid subtypes
(Table 1). In the normal monolayer ovarian surface epithelia, all
ovarian surface epithelial cells were stained positive for nuclear
GATA4 and GATA6 (Figure 1A). While GATA4 and GATA6
staining are absent or greatly reduced in most ovarian carcinomas
(Table 1). Among the informative cases, loss of GATA4 was found
in 81/82 (99%) of serous carcinomas, 1/12 (8.3%) of mucinous
carcinomas, 11/12 (92%) of clear cell carcinomas, and 5/5 (100%)
of endometroid carcinomas. Loss of GATA6 was found in 55/82
(67%) of serous carcinomas, 1/12 (8.3%) of mucinous carcinomas,
10/12 (83%) of clear cell carcinoma, and 5/5 (100%) of
endometroid carcinomas. Examples of the immunostainings are
shown in Figure 1, for a GATA4- and GATA6-negative serous
carcinoma (Figure 1B), a GATA4-negative but GATA6-positive
serous carcinoma (Figure 1C), a GATA6-negative but GATA4-
positive serous carcinoma (Figure 1D), and a GATA4 and
GATA6-positive mucinous carcinoma (Figure 1E). It is also
noticeable that some GATA4 and/or GATA6 staining is present
in stromal cells in both normal and timorous ovaries, though most
of these staining are not as intense as those of the epithelial cells. In
some cases as seen in the tumor shown in Figure 1B, some small
stromal cells, likely immune and lymphocytic cells, show strong
nuclear staining of GATA4.
One striking feature of GATA4 and GATA6 staining is that
though GATA4 and GATA6 are lost in most ovarian cancer
(predominantly serous subtype), carcinomas of the mucinous
subtype are mostly GATA4- and GATA6-positive (Table 1). Thus,
the expression of GATA4 and GATA6 distinguishes mucinous
carcinomas from other histological subtypes.
Loss of GATA4 precedes loss of GATA6 in pre-neoplastic
ovarian surface and cyst epithelia
GATA4 expression is absent in the majority of serous ovarian
cancer, and GATA6 is also absent in many but also positive in some
cases (Table 1). Negative GATA6 and positive GATA4 exist only in
rare cases of ovarian carcinomas. Thus, loss of GATA4 appears to
be more prevalent than loss of GATA6 in ovarian cancer.
Table 1. Expression of GATA4 and GATA6 in ovarian cancer
histological subtypes.
Histological
Subtypes GATA4 GATA6
Negative Positive Negative Positive
Serous 81/82 (99%) 1/82 (1.2%) 55/82 (67%) 27/82 (33%)
Mucinous 1/12 (8.3%) 11/12 (92%) 1/12 (8.3%) 11/12 (92%)
Clear Cell 11/12 (92%) 1/12 (8.3%) 10/12 (83%) 2/12 (17%)
Endometrioid 5/5 (100%) 0/5 (0%) 5/5 (100%) 0/5 (0%)
GATA4 and GATA6 immunostaining in 111 cases of ovarian carcinomas in TMA..
doi:10.1371/journal.pone.0006454.t001
GATA Factors in Ovarian Cancer
PLoS ONE | www.plosone.org 2 July 2009 | Volume 4 | Issue 7 | e6454Figure 1. Immunostaining of GATA4 and GATA6 in ovarian cancer histological subtypes. Immunostainings of GATA4 and GATA6 were
performed in 111 ovarian carcinomas including the 4 histological subtypes. The results are summarized in Table 1. A. Normal ovarian surface
epithelial cells are positive for both GATA4 and GATA6 in the nucleus. 2006magnification. B. An example of both GATA4- and GATA6-negative
serous carcinoma. 406magnification. C. An example of GATA4-negative and GATA6-positive serous carcinoma. 406magnification. D. An example of
GATA4-positive and GATA6-negative serous carcinoma. 406magnification. E. An example of both GATA4- and GATA6-positive mucinous carcinoma.
406magnification. E, epithelium; T, tumor; S, stroma.
doi:10.1371/journal.pone.0006454.g001
Figure 2. Loss of GATA4 and GATA6 in pre-malignant lesions. Immunostaining of GATA4 and GATA6 in morphologically normal ovarian
surface and/or cyst epithelia found in ovarian carcinomas. A. An ovarian surface epithelium is positive for GATA6 and negative for GATA4. Positive
GATA4 staining in stroma is noted. B. An ovarian surface epithelium is positive for GATA6 and negative for GATA4. Both GATA4 and GATA6 are lost in
cyst epithelial cells adjacent to the surface. 2006magnification. E, epithelium; C, cyst; S, stroma.
doi:10.1371/journal.pone.0006454.g002
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phological changes were observed in prophylactic oophorectomies,
showing the usefulness of these tissues in studying the initiation of
ovarian epithelial cancer [37]. In the current analysis, the 26 cases
of ovarian tissues from prophylactic oophorectomies were found to
contain no microscopic tumors, but did exhibit morphologically
altered lesions derived from ovarian surface or cyst epithelia [36].
In some overt ovarian carcinomas, morphologically normal
monolayers of epithelial cells can be found adjacent to malignant
cells. Just because of the physical proximity, these morphological
normal epithelial cells may share some features with the neoplastic
cells. By immunostaining, we found that in the majority of the
cases GATA4 is absent and GATA6 is positive in the single
layered, morphologically benign lesions, as shown by an example
(Figure 2A). In a second example, ovarian epithelial cells lining the
surface are positive for GATA6 and negative for GATA4, and the
epithelial cysts beneath the surface lost both GATA4 and GATA6
expression (Figure 2B).
Each slides of the 26 samples contains variable numbers of
lesions with variable degrees of morphological changes. We have
examined about 80 of these lesions to make several general
descriptions: GATA4 is negative in about 80% of surface epithelia,
and GATA4 is absent in nearly all obvious lesions and also about
half the morphologically normal monolayers. GATA6 is generally
present (70%) in the epithelial lesions, and loss of GATA6
correlates with neoplastic morphological changes (multiple epi-
thelial layering) in about 90% of the cases. Thus, GATA4 loss
often precedes GATA6 loss, and loss of GATA4 and GATA6
occurs prior to malignant transformation of ovarian surface
epithelial cells.
Loss of GATA4 and/or GATA6 closely correlates with
epithelial morphological transformation
Over the years, we assembled a collection of 12 ovarian
carcinomas that contain lesions of contiguous epithelia linking
morphologically benign epithelial cells to overt cancer cells [35].
Such lesions have also been described previously for mucinous and
serous ovarian cystadenocarcinomas [38]. We reasoned that the
presence of a transition from benign to malignant may be useful to
determine the involvement of candidate genes in ovarian epithelial
tumorigenesis. Indeed, in all 12 cases of benign to neoplastic
transitions analyzed, loss of GATA4 and/or GATA6 closely
associates with neoplastic morphological transformation. In the
first example (Figure 3A), GATA4 is already absent in the benign
monolayer; GATA6 is positive in the monolayer cells but is lost in
the adjacent cancer cells. Loss of GATA6 closely correlates with
the loss of its transcription target Dab2 (Figure 3A). In a second
example, GATA4 and GATA6 expression are lost simultaneously,
closely associated with loss of Dab2 and morphological transfor-
mation (Figure 3B). The enlarged benign to neoplastic transition
site (Figure 3B, lower panels) shows that GATA4 is abruptly lost,
and GATA6 is greatly reduced on the transition.
Thus, the loss of GATA6 expression correlates closely with
neoplastic transformation of the ovarian surface epithelium, as
observed in contiguous ovarian surface epithelium connecting
morphologically normal to malignant cells (Figure 3). In previous
studies [18,35], the ovarian surface epithelium immediately
adjacent to tumor areas was considered to be pre-neoplastic.
These pre-neoplastic lesions often lack an intact basement
membrane as indicated by the absence of collagen IV and laminin
staining, as well as the loss of Dab2 expression [35]. In the
morphologically normal epithelia immediately adjacent to tumor
areas, both GATA6 and Dab2 are positive. However, the
contiguously connected neoplastic cells are negative for both
GATA6 and Dab2 staining. The neoplastic cells in the
transformed epithelium that is immediately connected to the
morphologically normal ovarian surface epithelial cells are likely
most similar to the normal, and thus are considered early tumor
cells. Such analysis suggests the possibility that the loss of GATA6
is one of the causative factors of ovarian epithelial transformation.
The observations from human ovarian cancer tissues suggests
that loss of GATA4 expression often precedes the loss of GATA6,
and the loss of GATA6, correlated with the loss of Dab2,
associates with epithelial morphological transformation.
Reduction of GATA factor expression upon passaging of
ovarian surface epithelial cells in primary cultures
Over the last 5 years in the studies of GATA factors in ovarian
surface epithelial and culture cells, we found that GATA4 is absent
in most ovarian cancer cell lines and also SV-40-transfected,
‘‘immortalized’’ ovarian surface epithelial cells [17,18]. Addition-
ally, GATA4 expression was variable in primary cultures of
human ovarian surface epithelial cells. Thus, we speculate that the
expression of GATA4 is not stable in ovarian surface epithelial
cells and may gradually reduce over time.
To test this idea, we carefully followed the passages of primary
ovarian surface epithelial cells in culture overtime and monitored
the expression of GATA4, GATA6, and Dab2 genes. The ovarian
surface epithelial cells were harvested from ovaries from
prophylactic oophorectomies as described previously [17,18].
The tissues were examined and were determined to be
morphologically normal and void of microscopic tumors. The cell
doubling time was about two week initially and shortened to one
week to 5 days in later passages. We have carried out the passages
of a HOSE cell preparation (ROE 1005816) to passage 10 over a
two-month period and the cells were still highly proliferative at the
end. Typically, the cells can grow in culture for about 20 passages
over a 6-month period before undergoing replicative senescence.
At each passage, half of the cells were harvested and used for
expression analysis, and the other half was maintained continu-
ously in culture.
First, the changes in the morphology of the ovarian surface
epithelial cells were obvious. Initially, the cells appeared to be
round and flat, with a ‘‘cobblestone’’ morphology, and increas-
ingly the cells became elongated and spindle-like, and the most
dramatic changes was observed at passage 4 (Figure 4A). GATA4
mRNA levels were found to reduced rapidly, and became
undetectable by passage 4 (Figure 4B,C). The expression of
GATA6 and its transcription target Dab2, reduced gradually over
time, and the mRNA levels of both genes were 20–30% of the
original cells (Figure 4C). As a control, house-keeping gene TBP
(TATA box binding protein, accession number NM_003194)
expression level had insignificant changes over the course of the
culture, and the variation probably reflects the range of error of
the assay.
Thus, all GATA4, GATA6, and Dab2 mRNA levels are
reduced upon passaging of the primary ovarian surface epithelial
cells in culture. The loss of GATA4 precedes the loss of GATA6
(and Dab2), similar to the observation in the pre-neoplastic
ovarian epithelia adjacent to ovarian carcinomas, where GATA4
is often lost prior to GATA6. Previously, the loss of GATA4 and
GATA6 in ovarian cancer and epithelial cells was demonstrated to
be by the mechanism of hypoacetylation of histones H3 and H4
and loss of histone H3/lysine K4 trimethylation at their promoters
[18]. Gene expression is determined by the pattern of associated
histone modification, known as the histone codes [39]. Loss of
histone acetylation leads to a more compact chromatin confor-
mation and loss of transcriptional activity [40], and histone H3/
GATA Factors in Ovarian Cancer
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readily loss of GATA4 and GATA6 expression suggests the
instability of the epigenetic states/chromatin conformation,
consistent with the early loss of GATA factors in ovarian
tumorigenesis.
Alteration of chromatin modification at GATA4 locus
associated with loss of expression upon passaging of
ovarian surface epithelial cells in primary cultures
To determine the cause of the reduction of GATA factor
expression in primary cultures, we first determine the expression in
a large panel of ovarian surface epithelial cells and cancer cells.
Total RNA was isolated from 8 preparations of primary HOSE
cells (from 7 persons, here, C.47 and D.47 were split from the
same HOSE preparations but were cultured by different lab staff),
6 HIO lines which are HOSE cells transfected with SV40-T-
antigent to prolong culturing life span, and 6 lines of ovarian
cancer cells (Figure 5). The RNA was subjected to semi-
quantitative RT-PCR (Figure 5A) and real-time RT-PCR
(Figure 5B) to determine mRNA levels for GATA4, GATA6,
Dab2, and GAPDH or BHD as loading controls. GATA4
expression is reduced in some HOSE preparations and HIO
lines, and is absent in all cancer lines as determined by both
Figure 3. Loss of GATA4 and/or GATA6 closely correlates with epithelial morphological transformation. Examples of human ovarian
cancer stained for GATA4, GATA6, and Dab2 in adjacent tumor sections. A. An ovarian surface epithelium that consists of a morphological normal
surface epithelium (arrow head) contiguously linking malignant cells (arrow) that have either invaded into stroma or expanded into areas around the
ovary. GATA4 is negative in both morphological normal or neoplastic epithelial cells. The epithelial cells in the morphological normal epithelium are
positive for GATA6 and Dab2, and the malignant cells are negative for GATA6 and Dab2. Some scattered cells in the stroma are Dab2 positive but
negative for GATA6. These cells are macrophages in which Dab2 expression is not GATA6-dependent. B. In this ovarian carcinoma, the epithelial cells
in the morphological normal epithelium are positive for GATA4, GATA6, and Dab2, and the adjacent malignant cells are negative for GATA4, GATA6,
and Dab2. The images were taken under a microscope with a 1006magnification. The stainings for GATA4 and GATA6 in the transition in panel B are
shown in a higher magnification (4006) at the lower panels. E, epithelium; C, cyst; S, stroma; T, tumor.
doi:10.1371/journal.pone.0006454.g003
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PLoS ONE | www.plosone.org 5 July 2009 | Volume 4 | Issue 7 | e6454Figure 4. Reduction of GATA4 and GATA6 expression upon culturing of ovarian surface epithelial cells. Human ovarian surface
epithelial cells were isolated from morphologically normal human ovaries obtained from oophorectomy surgery. The cells were passaged 10 times
over a period of 3 months, and cells were harvested from each passage for mRNA analysis. A. Morphology of the cells in passage #1, 2, 4, 6, 8, 10. B.
The total RNA were used for quantitative real-time RT-PCR to assay mRNA levels. The results are presented as a ‘‘heat-map’’. C. The amount of mRNA
relative to passage 1 was quantitated and presented as a bar graph.
doi:10.1371/journal.pone.0006454.g004
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Reduction of GATA6 and Dab2 expression in HIO and cancer
lines is more apparent by real-time RT-PCR (Figure 5B).
We were able to obtain a sufficient amount of 3 primary HOSE
cells (HOSE.96, HOSE.47, and HOSE.63) for further study of
changes in chromatin modification of the GATA4 and GATA6
locus by ChIP assay during passaging of the cells in cultures. The
expression levels of GATA4 inversely correlate with passage
number of the cells: HOSE.96 (or C.96) cells, passage #3, have
high GATA4 expression; HOSE.47 cells, passage #5, have a
lower GATA4 level; and HOSE.63 cells, passage # 12, have a
much reduced expression level (Figure 5B).
Following the previously established protocol for ChIP assay for
GATA4 and GATA6 genes [18], we found that, indeed, at a site
immediately up-stream of the GATA4 Exon 1 (Figure 5C), the
reduction of GATA4 expression levels correlates with the loss of
acetylation of Histone H3 and H4 (Figure 5D). No significant
changes were seen for di and tri methylation of H3K4, markers for
active chromatin conformation [41,42]. However, dimethylation
of histone H3 at lysine 9 and 27 (Me2H3K9, Me2H3K27) and
HP1 is absent, suggesting the silenced GATA4 gene is not being
incorporated into heterochromatin [43].
Beside the reduced acetylation of histone H3 and H4 in A2780
cells, the patterns of histone modification at the GATA6 locus
(Figure 5E) is similar between HOSE cells and cancer lines
OVCAR3 and OVCAR10 (Figure 5F), suggesting the alteration of
histone modification at GATA6 locus is not a general event in
ovarian epithelial and cancer cells.
Figure 5. Alterations of histone modifications at GATA4 locus in culturing of ovarian surface epithelial cells. Human ovarian surface
epithelial cells were isolated from morphologically normal human ovaries obtained from oophorectomy surgery. Several HIO lines were also
established by transfecting the primary cells with SV-40 T-antigen to prolong the life span in cultures. Total RNA isolated from a collection of primary
HOSE, HIO, and cancer cells were used for: A. Semi-quantitative RT-PCR, and B. Quantitative real-time RT-PCR, to assay mRNA levels for GATA4,
GATA6, Dab2, and GAPDH (semi-quantitative RT-PCR) or BHD (real-time RT-PCR) as loading controls. Sufficient RNA were obtained from HOSE.96 (or
C.96), passage #3; HOSE.47 cells, passage #5; and HOSE.63 cells, passage # 12; for CHIP assay. C. The location of primers F3 and R3 at GATA4 gene
for PCR in the ChIP assay is shown. D. Lysates from HOSE.96, HOSE.47, HOSE.63, ES2, SKOV3, A2780, OVCAR3, and OVCAR10 were prepared for CHIP
assay. Chromatin precipitations by antibodies to Ac H3, Ac H4, Me2H3K4, Me3H3K4, Me2H3K9, Me2H3K27, and HPc1 were used to amplify by PCR
using primers F3 and R3. The input signal (‘‘in’’, 2% of total chromatins used for immunoprecipitation), no antibody control (‘‘no’’), and no template
control (‘‘H2O’’) were included. The bright field images of the semi-quantitative PCR products are shown. E. The location of primers F2 and B2 at
GATA6 gene for PCR in the CHIP assay is shown. F. Lysate from HOSE.96, HOSE.47, A2780, OVCAR3, and OVCAR10 were prepared for CHIP assay. The
bright field images of the semiquantitative PCR products are shown.
doi:10.1371/journal.pone.0006454.g005
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heterogeneous mice
Finding a close correlation between the loss of GATA6 and
epithelial transformation prompted us to speculate that the loss of
GATA6 may be causative in the transformation of ovarian surface
epithelial cells. The above observations also suggest that the loss of
GATA6 may be more critical than the loss of GATA4 in
promoting ovarian epithelial transformation. To determine the
consequence for the loss of GATA6 in ovarian surface epithelia,
we investigated the ovarian phenotype of GATA6 (+/2) mice,
since the homozygous mice are embryonic lethal [24,25]. We have
obtained and maintained a colony of GATA6 knockout mice over
the last 2 years. Ovarian tissues were harvested from the mice at
around one year of age, and morphology of ovaries from
littermates of GATA6 (+/2) and wildtype were compared.
Strikingly, all ovaries of GATA6 (+/2) genotype exhibited some
abnormalities (Table 2): Some ovaries have extensive proliferative
lesions of the surface epithelia (Figure 6A), and the others have
large ovarian cysts that are positive for cytokeratin (Figure 6B).
The ovarian phenotype resembles those of dab2 (+/2) mice [32],
consistent with Dab2 as a GATA6 transcription target and
mediator [27].
Thus, this result suggests GATA6 deficiency influences ovarian
surface epithelia, possibly promoting transformation though tissue
specific deletion of GATA6 in ovarian surface epithelial cells will
be a better test, when GATA6 conditional knockout mice become
available.
Discussion
This study examined the expression of GATA 4 and GATA6 in
ovarian surface epithelial cells and carcinomas in detail, and found
that the loss of GATA4 is more wide spread and often precedes
GATA6 in the transformation of ovarian surface epithelia. The
loss of GATA6, however, correlates closely with the morphological
transformation of the epithelia. The readily reduction of GATA4
and GATA6 expression upon culturing of the ovarian surface
epithelial cells suggests the instability of the epigenetic state/
chromatin conformation of GATA4 and GATA6 locus, consistent
with the early loss in ovarian tumorigenesis. The early loss of
GATA4 and GATA6 and the close correlation with the neoplastic
transformation of ovarian surface epithelia suggests a causative
role, which is supported by the prevalence of ovarian epithelial
lesions in GATA6 heterozygous deficient mice [32].
In contrast to other histological subtypes, mucinous ovarian
carcinomas generally are positive for GATA4 and GATA6
expression. Indeed, the morphology of mucinous ovarian carci-
nomas is very unique in that the cancer cells appear to retain
apical polarity and often exist as monolayer epithelia.
The quickly loss of GATA4 in passaging of primary cells in
culture is intriguing. The loss of GATA4 expression in passaging of
primary cells in culture associates with loss of H3 and H4 histone
acetylation at the GATA4 promoter locus. The loss of GATA4 in
cancer cell lines appears also mediated by the reduction of H3 and
H4 histone acetylation of the promoter locus. Thus, it may be
speculated that chromatin changes led to the loss of GATA4
occurs at the very early stage of ovarian epithelial transformation.
Loss of GATA4 itself may not present any phenotype. However,
the loss of GATA4 may lead to the destabilization of the gene
expression profile of the differentiated ovarian surface epithelial
cells. Further changes may lead to loss or reduction of GATA6
expression. The loss of GATA6, and subsequently its transcription
target Dab2, may be causative for morphological transformation
of ovarian surface epithelia.
The finding of the loss of GATA4 at the very early, non-
phenotypic stage preceding ovarian surface epithelial tumorigen-
esis may provide insight to the risk factors and initial step in the
development of ovarian cancer. The ovarian phenotypes of
heterozygous GATA6 knockout mice suggest a causative role for
the loss of GATA factors in ovarian tumorigenesis. Further
evidence may be obtained by examining conditional GATA4 and
GATA6 knockout mice that can bypass the requirement of GATA
factors in embryonic development.
Materials and Methods
Ovarian Tissues and Tumor Specimens and
Immunohistochemistry
Cancerous and benign ovarian specimens were obtained from
patients who underwent surgical resection at Fox Chase Cancer
Center. The 3 ovarian tumor tissue microarrays (TMAs) and 20
prophylactic oophorectomies were provided by the Tumor Bank
Facility of Fox Chase Cancer Center. We also used a collection of
38 separate cases of archived ovarian tumor tissue blocks. The
tumors were histologically classified according to the World Heath
Organization (WHO) classification and the surgical stages were
determined according to the classification of International
Federation of Gynecology and Obstetrics (FIGO). Prior to
surgeries, a blanket informed consent was obtained from the
patients in written for the agreement of general laboratory study of
the tissues following pathological diagnosis. The current study of
human ovarian tissues and tumor samples was reviewed and
approved by the Fox Chase Cancer Center IRB (Institutional
Review Broad). The tissues were coded and disconnected from
patient names and personal information prior to collection by the
Institutional Tumor Bank, and the study was considered exempted
by the IRB.
Immunostaining was performed using the mouse DAKO
Envision TM
+ System and the Peroxidase (DAB) Kit (Dako
Corporation, Carpinteria, CA, USA) as previously described
[17,36]. The antibodies used include: anti-GATA6, anti-GATA4,
anti-Dab2/p96 (1:400 dilution, clone 52, BD Transduction
Laboratories, Lexington, KY). Negative controls were prepared
by replacing the primary antibody with mouse non-immunized
IgG. Evaluation of the staining intensity and characteristics were
performed independently by two pathologists in a blinded manner.
Tumors with more than 10% of tumor cells or stromal area
showing strong to moderate staining are scored as positive.
Cell Culture
The panel of human ‘‘immortalized’’ ovarian (HIO) epithelial
cell lines [17], two preparations of primary human ovarian surface
epithelial cells [36], and ovarian cancer cell lines were analyzed.
Ovarian cancer cells OVCAR2, -3, -4, -5, -8, and -10 were
collected in Dr. Andrew Godwin’s lab and were used previously
[17]. Other ovarian cancer cells including A2780, ES2, and
SKOV3 were purchased from American Type Culture Collection
(ATCC), where information about these ovarian cancer cells is
available. The primary and HIO- ovarian surface epithelial cells
were cultured in medium 199 and MCDB 105 (1:1) supplemented
with 15% FBS, 0.25 U/ml insulin, 2 mM L-glutamine, 100 U/ml
penicillin and 100 mg/ml streptomycin.
Primary cells cultured between passages 2-4 were used for
experiments. The ovarian cancer cell lines were cultured in RPMI
1640 supplemented with 10% FBS, 2 mM L-glutamine, 100 U/
ml penicillin and 100 mg/ml streptomycin. The cultures were
maintained in a humidified atmosphere of 95% air/5% CO2 at
37uC.
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Path. No. Age (Month) Inclusion Cyst Papillomatosis Epithelial Hyperplasia notes
06-4201 10 - ++
06-4418 7 - - - Uterine epithelial hyperplasia
06-4222A 15.5 M - - -
06-4223A 15.5 - - -
06-4224A 15.5 + - + Ovarian cystadenoma, uterine cystic change
06-4225A 15.5 - - - Lymphoma in ovary
06-4226A 15.5 - + - Ovary atrophy
06-4227A 14.5 - - -
06-4228A 14.5 - - - Ovarian cystadenoma
06-4229B 16 - - -
06-4230 16 - + -
06-4231 12 - - -
06-4232 11.5 - - -
06-4446 14 - - -
06-4447 15.5 - - - Lymphoma in ovary
06-4448 18 - - - Lymphoma in ovary
06-4449 15.5 - - -
06-4450 18 ++ -
06-4452 15.5 - - +
06-4455 13.5 - - -
06-4456 13.5 + - +
06-4458 13.5 + - +
06-4459 13 - - -
06-4460 13 + --
06-4461 13 - - -
06-4462 13 - - -
06-4483 17 - - - -
06-4892 24 + -- -
06-4893 16.5 + -- -
06-4899 15.5 - - - -
06-4901 16 - - - -
06-4902 16 - - - -
06-4903 16 - - - -
07-5780 12 + -- -
07-5781 15 - + --
08-4142 12 - - - -
08-4143 13 + -- -
08-4144 13 - - - -
08-4145 13 - - - -
08-4146 13 + -- -
08-4147 13 - - - -
08-4148 13 - - - -
08-4149 13 - - - -
08-4150 13 + -- -
08-4151 13 - - -
08-4152 13 + - ++ Extensive ovarian surface hyperplasia
08-4154 13 - - -
A total of 47 GATA6 (+/2) mice were analyzed for ovarian phenotype. The majority of mice were analyzed between the age of 12–18 months. Ovarian tissues were
harvested and subjected to histological analysis. More than 20 wildtype littermates were also analyzed as controls. The 47 GATA6 (+/2) mice exhibited the presence of
ovarian inclusion cysts in 12 (26%), surface papillomatosis in 5 (11%), and hyperplasia of surface epithelial cells in 6 (13%). Only one in the 20 wildtype mice of same age
range showed mild surface papillomatosis.
doi:10.1371/journal.pone.0006454.t002
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Chromatin immunoprecipitation (ChIP) was carried out using
the ChIP assay kit (Upstate Biotechnology Laboratories) essentially
as sugggested by the manufacturer and described in details
previously [18]. The procedures for real time quantitative and
semiquantitative RT-PCR was also described previously [18].
GATA6-deficient Mice and tissue analysis
The founder pair of GATA6 knockout mice was a gift from Dr.
Edward Morrisey (University of Pennsylvania) [25]. The colonies
were maintained by inbreeding in the Animal Facility of Fox
Chase Cancer Center following the protocol of published work
[25].
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